Pro Medicus

AI didn't kill ASX SaaS stocks – it killed the multiples investors would pay for them. That distinction could make or break your portfolio.

The market's hottest stock is off 32% in weeks, so is this an opportunity to buy the dip or sign of worse to come? We asked two investors.

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

We sat down with Pro Medicus CEO, Dr Sam Hupert on results day to discuss the past six months and the all-important outlook.

Shares of Pro Medicus, Technology One, Wisetech Global and Xero have soared in 2024, but how much upside remains for those who invest now?

There are only two states in software according to Pro Medicus CEO Dr Sam Hupert: "quick or dead". And Hupert doesn't much care to be dead.

One of Australia's premier mid-caps has handed down its first-half results. But has it managed to surprise the market yet again?

Healthcare is a tough space in which to win. With high barriers to entry and many problems to solve, finding and dominating your niche can be one of the many...